Combined Angiotensin Receptor/Neprilysin Inhibitors: A Review of the New Paradigm in the Management of Chronic Heart Failure

Clinical Therapeutics

Volumn 37, Issue 10, 2015, Pages 2199-2205

  Macdonald, Peter S ^a  

^a ST VINCENT S HOSPITAL   (Australia)

Author keywords

angiotensin II receptor blockers; ARNI; ejection fraction; heart failure; neprilysin inhibitors

Indexed keywords

ANGIOTENSIN 1 RECEPTOR ANTAGONIST; ANGIOTENSIN RECEPTOR ANTAGONIST; BRADYKININ; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; ENKEPHALINASE INHIBITOR; NATRIURETIC FACTOR; SACUBITRIL PLUS VALSARTAN; AMINOBUTYRIC ACID DERIVATIVE; G PROTEIN COUPLED RECEPTOR; MEMBRANE METALLOENDOPEPTIDASE; ONCOPROTEIN; PROTO-ONCOGENE PROTEINS C-MAS-1; TETRAZOLE DERIVATIVE;

ADVERSE DRUG REACTION; ANGIONEUROTIC EDEMA; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; HEART EJECTION FRACTION; HEART FAILURE; HUMAN; LARGE SCALE PRODUCTION; MEDIATOR RELEASE; MORBIDITY; MORTALITY; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PREVALENCE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; RISK BENEFIT ANALYSIS; RISK REDUCTION; ANTAGONISTS AND INHIBITORS; CHRONIC DISEASE; COMBINATION DRUG THERAPY; DRUG EFFECTS;

AMINOBUTYRATES; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANGIOTENSIN RECEPTOR ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CHRONIC DISEASE; DRUG THERAPY, COMBINATION; ENALAPRIL; HEART FAILURE; HUMANS; NEPRILYSIN; PROTO-ONCOGENE PROTEINS; RECEPTORS, G-PROTEIN-COUPLED; RENIN-ANGIOTENSIN SYSTEM; TETRAZOLES;

EID: 84945436604     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2015.08.013     Document Type: Review

References (27)

1. M. Packer Evolution of the neurohormonal hypothesis to explain the progression of chronic heart failure Eur Heart J 16 Suppl F 1995 4 6
2. K. Swedberg Importance of neuroendocrine activation in chronic heart failure. Impact on treatment strategies Eur J Heart Fail 2 2000 229 233
3. M.C. Shibata, M.D. Flather, and D. Wang Systematic review of the impact of beta blockers on mortality and hospital admissions in heart failure Eur J Heart Fail 3 2001 351 357
4. J.J. McMurray CONSENSUS to EMPHASIS: the overwhelming evidence which makes blockade of the renin-angiotensin-aldosterone system the cornerstone of therapy for systolic heart failure Eur J Heart Fail 13 2011 929 936
5. H. Nakagawa, and et al. Atrial natriuretic peptide locally counteracts the deleterious effects of cardiomyocyte mineralocorticoid receptor activation Circ Heart Fail 7 2014 814 821
6. E. Jungmann, and et al. Effect of human atrial natriuretic peptide on blood glucose concentrations and hormone stimulation during insulin-induced hypoglycaemia in healthy man Eur J Clin Pharmacol 36 1989 593 597
7. K. van der Zander, and et al. Hemodynamic and renal effects of low-dose brain natriuretic peptide infusion in humans: a randomized, placebo-controlled crossover study Am J Physiol Heart Circ Physiol 285 2003 H1206 H1212
8. N. Hata, and et al. Effects of carperitide on the long-term prognosis of patients with acute decompensated chronic heart failure: the PROTECT multicenter randomized controlled study Circ J 72 2008 1787 1793
9. C.M. O'Connor, and et al. Effect of nesiritide in patients with acute decompensated heart failure N Engl J Med 365 2011 32 43
10. D.E. Newby, and et al. Candoxatril improves exercise capacity in patients with chronic heart failure receiving angiotensin converting enzyme inhibition Eur Heart J 19 1998 1808 1813
11. M.T. Rademaker, and et al. Combined neutral endopeptidase and angiotensin-converting enzyme inhibition in heart failure: role of natriuretic peptides and angiotensin II J Cardiovasc Pharmacol 31 1998 116 125
12. N.C. Trippodo, and et al. Vasopeptidase inhibition with omapatrilat improves cardiac geometry and survival in cardiomyopathic hamsters more than does ACE inhibition with captopril J Cardiovasc Pharmacol 34 1999 782 790
13. J.B. Kostis, and et al. Omapatrilat and enalapril in patients with hypertension: the Omapatrilat Cardiovascular Treatment vs. Enalapril (OCTAVE) trial Am J Hypertens 17 2004 103 111
14. J.L. Rouleau, and et al. Comparison of vasopeptidase inhibitor, omapatrilat, and lisinopril on exercise tolerance and morbidity in patients with heart failure: IMPRESS randomised trial Lancet 356 2000 615 620
15. R.M. Fryer, and et al. Effect of bradykinin metabolism inhibitors on evoked hypotension in rats: rank efficacy of enzymes associated with bradykinin-mediated angioedema Br J Pharmacol 153 2008 947 955
16. M. Packer, and et al. Comparison of omapatrilat and enalapril in patients with chronic heart failure: the Omapatrilat Versus Enalapril Randomized Trial of Utility in Reducing Events (OVERTURE) Circulation 106 2002 920 926
17. M.J. Bloch, and J.N. Basile Combination angiotensin receptor blocker-neutral endopeptidase inhibitor provides additive blood pressure reduction over angiotensin receptor blocker alone J Clin Hypertens (Greenwich) 12 2010 809 812
18. J. Gu, and et al. Pharmacokinetics and pharmacodynamics of LCZ696, a novel dual-acting angiotensin receptor-neprilysin inhibitor (ARNi) J Clin Pharmacol 50 2010 401 414
19. P.P. Prasad, and et al. Pharmacokinetics of multiple doses of valsartan in patients with heart failure J Cardiovasc Pharmacol 40 2002 801 807
20. L.M. Ruilope, and et al. Blood-pressure reduction with LCZ696, a novel dual-acting inhibitor of the angiotensin II receptor and neprilysin: a randomised, double-blind, placebo-controlled, active comparator study Lancet 375 2010 1255 1266
21. J.J. McMurray, and et al. Dual angiotensin receptor and neprilysin inhibition as an alternative to angiotensin-converting enzyme inhibition in patients with chronic systolic heart failure: rationale for and design of the Prospective comparison of ARNI with ACEI to Determine Impact on Global Mortality and morbidity in Heart Failure trial (PARADIGM-HF) Eur J Heart Fail 15 2013 1062 1073
22. J.J. McMurray, and et al. Angiotensin-neprilysin inhibition versus enalapril in heart failure N Engl J Med 371 2014 993 1004
23. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. The SOLVD Investigators. N Engl J Med, 1991. 325:293-302.
24. A.S. Desai, and et al. Effect of the angiotensin-receptor-neprilysin inhibitor LCZ696 compared with enalapril on mode of death in heart failure patients Eur Heart J 7 36 2015 1990 1997
25. M. Packer, and et al. Angiotensin receptor neprilysin inhibition compared with enalapril on the risk of clinical progression in surviving patients with heart failure Circulation 131 2015 54 61
26. M.T. Vidan, and et al. FRAIL-HF, a study to evaluate the clinical complexity of heart failure in nondependent older patients: rationale, methods and baseline characteristics Clin Cardiol 37 2014 725 732
27. S.D. Solomon, and et al. The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomised controlled trial Lancet 380 2012 1387 1395